Editorials The Power and Pitfalls of Simplifying Assumptions
The technical note by Paltiel and Kaplan exemplifies the tension between simplifying assumptions and clinical realism in the development of a model of a clinical condition. All models are abstractions, and the use of simplifying assumptions to render a model tractable is a powerful tool. However, the computational ease carries the price that the model may not accurately represent the underlying clinical processes.
The appropriate clinical detail, time horizon, and precision of a model's parameters are dependent upon the model's intended use. Models designed to provide insights about the relationships between variables or the direction of effect of a variable, or to illustrate a specific methodologic characteristic, need only be sufficiently detailed to elucidate the behavior of interest. However, models designed to answer specific clinical questions or to affect clinical or social policy have more stringent requirements for clinically relevant detail. The paper by Paltiel and Kaplan investigates the effect of differential participation rates on estimates of cost-effectiveness for voluntary HIV screening programs. Using evidence that voluntary and involuntary screening programs uncover different infection rates, the authors conclude that HIV-positive individuals participate in screening at different rates than those who are HIV-negative. They demonstrate that one important consequence of differential participation is to create errors in estimates of the cost-effectiveness of HIV screening. The authors describe, through a simple but elegant model, the direction and magnitude of the effects of differential participation, and provide estimates of the magnitudes of these effects in different populations. The work is an excellent example of the power of a model to characterize a hypothesized relationship between a variable and an outcome.
However, clinicians are likely to be bothered by the simplifying assumption that voluntary participation is dependent upon the patient's actual (but unknown) serostatus, represented in the model by r, for infected individuals and r~ for those uninfected. It seems clinically implausible that groups of patients respond based on their unknown HIV status. Rather, it is likely that voluntary and involuntary programs uncover different infection rates because people present for screening in voluntary programs based on real or perceived risk of being HIV-positive, as well as other factors, not actual HIV serostatus. The observed population-based participation rates r, and r are complex summations of subpopulations of infected and uninfected individuals, with varying participation rates affected by myriad social, demographic, psychological, and medical factors. Furthermore, it is likely that the variability in participation between different subgroups is greater than the variance between HIVnegative and HIV-positive populations. Although the assumption of serostatus-dependent, homogeneous participation rates simplifies the model and easily demonstrates that prior estimates of cost-effectiveness may be biased, it prevents the analysis from providing potential insights regarding how to alter participation. To understand the effectiveness of HIV screening programs, a knowledge of the reasons why participation rates appear to be different is necessary to understand how to develop programs that induce high-risk patients to be tested. Therefore, as a technical note, the report is accurate and describes an important error made in prior estimates of the cost-effectiveness of HIV screening programs that assume equal participation rates. However, as a vehicle to affect policy and understand how to improve appropriate participation, a more realistic model is required. Clinicians (perhaps inappropriately, but nevertheless predictably) will ignore models whose assumptions appear clinically incorrect. Because relaxing the strict serostatus assumption and linking participation rates to HIV-infection risk would add clinical credibility but be unlikely to alter the basic result, the presence of the assumption lessens the potential impact of this technically excellent work. Furthermore, one wonders whether additional insights would be found by making participation rates a function of the risk of HIV infection, and not serostatus itself.
At recent meetings, members of the Society for Medical Decision Making have engaged in soulsearching regarding why the techniques we develop and hold in high regard are not more universally accepted. The reasons are complex, but one component is a perceived lack of realism in models that are simplistic renditions of the world. Designing models with an appropriate level of detail is not trivial, but we need to create models that are believable reflections of the world to our clinical colleagues. In our quest to simplify models so that they are analytically tractable, we should heed the words of a scientist involved in modeling the behavior of the universe, arguably a task as complex as modeling a disease:
Everything should be made as simple as possible, but not simpler. Making 1997,17:490-5 
MDM Policy Regarding Financial Support of Authors
What should authors of manuscripts published in MDM tell editors, reviewers, and readers about their sources of financial support and their professional relationships to these sources? This is undoubtedly a timely question. The issue of conflict-of-interest rules is itself conflictual, and medical journals have taken a range of positions.' This editorial summarizes the background to MDM's position and states our current policy.
Recent instances of efforts of funding entities to influence or control the presentation of scientific findings include: 1) the effort of a pharmaceutical company to suppress publication of an article whose findings were less favorable toward one of their products than had been hoped for2-4; and 2) the alleged effort of a textile manufacturing plant to prevent a researcher from reporting on a possible outbreak of interstitial lung disease among workers in the plant.s 5 The common threads in these episodes are that a confidentiality agreement had been signed by the investigator as a condition of funding, that such an agreement appears to violate the long-standing academic tradition of freedom to publish, and that both universities involved declined to support their faculty members in the disputes. Rennie pointed out in his editorial that the agendas and culture of academia and industry are quite different.4 But similar issues have also arisen in the case of scientific research funded by the (US) Department of Defense and possibly other government agencies, so it is likely that efforts to control or influence the presentation and/or dissemination of research results are not limited to for-profit industries.
As readers of this journal know, MDM is planning to publish a special issue on Pharmaco-economics in 1998. Since pharmaceutical companies have an obvious interest in this area of research, issues surrounding financial disclosure and authorial independence have been of special concern. In the past year, extensive discussions have been conducted, in person and via e-mail, with the Publications Committee, the associate editors of the journal, and members of the editorial board. We have also examined the financial disclosure policies of a number of prominent medical journals. These discussions have culminated in formulating a policy for the journal. At the May meeting of the Society for Medical Decision Making Board of Trustees, a policy was discussed and adopted. Under this policy, disclosures are to be made in the following terms:
Financial support for this study was provided [choose one: entirely or in part] by a [choose one grant from or contract with] (here insert the name(s) of the funding source(s), whether a company, government agency, philanthropic foundation, institute, etc.). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing and publishing the report. [The following sentence should be inserted, if applicable] The following author(s) is/are employed by the sponsor : (identity employees).
A new paragraph containing this statement now appears in the Instructions for Authors. This statement should be included in the cover letter that accompanies any manuscript submitted to the journal
